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Role of TGFb-Mediated Inflammation in Cutaneous
Wound Healing
Xiao-Jing Wang1, Gangwen Han1, Philip Owens1, Yasmin Siddiqui1 and Allen Guanqun Li1
Among many molecules known to influence wound healing, transforming growth factor b1 (TGFb1) has the
broadest spectrum of actions, affecting all cell types that are involved in all stages of wound healing. Both
positive and negative effects of TGFb1 on wound healing have been reported. However, the underlying
mechanisms are largely unknown. We observed that endogenous TGFb1 was elevated in a narrow window of
time after injury, and transgenic mice constitutively overexpressing wild-type TGFb1 in keratinocytes
(K5.TGFb1wt) exhibited a significant delay in full-thickness wound healing as compared to non-transgenic
mice. Delayed wound healing was associated with profound inflammation throughout all stages of wound
healing in K5.TGFb1wt mice. Our data suggest that excessive and prolonged TGFb1 at the wound site does not
benefit wound healing, which is partially owing to its pro-inflammatory effect. Future studies need to be
conducted to assess whether tightly regulated TGFb1 expression will benefit wound healing. To this end, we
have developed a gene-switch TGFb1 transgenic system that allows TGFb1 induction in keratinocytes temporally
with desired levels. These mice will provide a tool to study stage-specific effects of TGFb1 on cutaneous wound
healing.
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INTRODUCTION
As the first barrier to the body, skin remains the first line of
defense against injury and disease. The cutaneous wound-
healing process is essential for the maintenance of skin
homeostasis. Impaired wound healing may lead to chronic
skin disorders (e.g., diabetic ulcers) accounting for significant
levels of morbidity as well as severe decrease in quality of
life. Excessive scarring resulting from deregulated wound
repair can also cause loss of joint motion or major body
deformation (Harding et al., 2002). A better understanding of
the cellular and molecular mechanisms during normal
wound healing will be instrumental for the development of
effective therapies for patients with aberrant wound healing.
Cutaneous wound healing proceeds via three overlapping
phases: inflammation, tissue formation, and tissue remodel-
ing (Singer and Clark, 1999). When the skin is injured, blood
constituents are released from disrupted blood vessels and a
blood clot forms. The platelets of the blood clot release
numerous chemotactic factors, particularly transforming
growth factor beta1 (TGFb1), which in turn rapidly recruit
leukocytes to accumulate at the site of injury and initiate the
inflammation phase. These leukocytes secrete chemokines
and inflammatory cytokines to augment the inflammatory
response that usually reach the peak within a few days after
injury. As the inflammation phase subsides, the tissue
formation phase takes place. The tissue formation phase
involves re-epithelialization and granulation tissue formation.
Upon injury, keratinocytes at the wound edge detach from
the basement membrane to acquire motility and migrate to
cover the wound. Initially, the re-epithelialization uses the
blood clot as a provisional matrix, which will be gradually
replaced with granulation tissue. A series of biological events
take place to promote granulation tissue formation, including
fibroblast activation and myofibroblast differentiation, extra-
cellular matrix degradation and production, and neovascu-
larization. The last stage of wound repair is the tissue-
remodeling phase, which includes changes in both the
epidermis and dermis. Particularly, the dermis underlying
the re-epithelialized epidermis undergoes a transition from
granulation tissue to fibrotic tissue, marked by the cessation
of neovascularization and the change of collagen synthesis
from collagen III to collagen I (Eckes et al., 2000). Finally, the
collagen synthesis slows down in the fibrotic tissue and a scar
form at the site of injury.
Normal wound healing is orchestrated by numerous
molecules, including growth factors, chemokines, inflamma-
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tory cytokines, and angiogenic factors produced by a variety
of cell types, including kerationcytes, fibroblasts, leukocytes,
and endothelial cells. Out of these molecules known to
influence wound healing, TGFb1 has the broadest spectrum
of actions, affecting all cell types that are involved in all
stages of wound healing (O’Kane and Ferguson, 1997). TGFb
is a family of pluripotent cytokines consisting of three
isoforms: TGFb1, 2, and 3. All TGFb isoforms are secreted
as latent forms, in which the N-terminal latency-associated
peptide remains non-covalently bound to the C-terminal
mature TGFb (Lawrence, 1991). The latent forms have to be
activated via proteolysis to release the mature TGFb before
functioning. TGFb acts via two types of transmembrane
serine/threonine kinase receptors. The major intracellular
mediators of TGFb family members are Smad proteins (for
reviews, see Derynck and Zhang, 2003; Shi and Massague,
2003; Feng and Derynck, 2005), which are divided into three
groups: receptor-specific Smads, a common Smad, and
inhibitory Smads. To date, eight Smad proteins (Smad1 to
Smad8) have been identified in mammals. Among them,
Smad2 and Smad3 function as receptor-specific Smads
specifically responsible for TGFb-mediated signaling (Liu
et al., 1997; Souchelnytskyi et al., 1997; Goto et al., 1998;
Miyazawa et al., 2002; Derynck and Zhang, 2003). When
TGFb binds to a type I–type II receptor complex, the type I
receptor kinase binds and phosphorylates receptor-specific
Smads. The phosphorylated receptor-specific Smads form
oligomeric complexes with Smad4, the common Smad,
which translocate into the nucleus and regulate gene
expression transcriptionally. The inhibitory Smads, Smad6
and Smad7, inhibit the TGFb-signaling cascade by either
blocking phosphorylation and subsequent nuclear transloca-
tion of signaling Smads (see for a recent review, Massague
et al., 2000; ten Dijke and Hill, 2004) or degradation of the
receptors via specific ubiquitin–proteasome pathways (Kav-
sak et al., 2000; Izzi and Attisano, 2004). Although Smads are
critical for TGFb signal transduction, compelling evidence
has suggested that Smad-independent pathways may also
mediate TGFb signaling. For instance, TGFb has been found
to activate mitogen-activated protein kinases, phosphoinosi-
tide 3-kinase, and Rho family guanosine triphosphatases to
regulate cell growth and apoptosis (Izzi and Attisano, 2004).
TGFb has been implicated in cutaneous wound healing in
regulating both Smad-dependent and-independent pathways
(Saika, 2004; Saika et al., 2004).
PARADOXICAL ROLE OF TGFb1 IN CUTANEOUS
WOUND HEALING
After injury, TGFb1 is rapidly upregulated and secreted by
keratinocytes, platelets, and macrophages (Singer and Clark,
1999). TGFb1 is essential for initiating inflammation and
granulation tissue formation (McCartney-Francis and Wahl,
1994). Additionally, TGFb1 may be required for cell
migration during wound repair. Some of the proteases that
are involved in cell migration, such as matrix metalloprotei-
nase (MMP)1, MMP2, MMP3, and MMP9, are transcription-
ally upregulated by TGFb1 (Madlener et al., 1998;
Santibanez et al., 2000; Ellenrieder et al., 2001; Verrecchia
et al., 2001). Cell migration-associated integrins, such as b1,
a5, av, b5, and b6, are also regulated by TGFb1 (Gailit et al.,
1994; Zambruno et al., 1995). These integrins affect
keratinocyte and fibroblast migration (Gailit et al., 1994;
Zambruno et al., 1995). TGFb1 has also been shown to
stimulate wound contraction (Montesano and Orci, 1988)
through its direct induction of a-smooth muscle actin
expression in fibroblasts (Desmouliere et al., 1993). Further-
more, TGFb1 stimulates the production of extracellular
matrix molecules, including collagens and fibronectin, which
strengthen the repaired wound. Reduced TGFbl expression
has been observed in humans with impaired wound healing
(Schmid et al., 1993; Cowin et al., 2001; Jude et al., 2002),
particularly in diabetic foot ulcers and chronic venous leg
ulcers (Cowin et al., 2001; Jude et al., 2002). In addition,
many animal models of impaired wound healing exhibit
reduced TGFb1 expression and the rate of healing is
improved by the application of exogenous TGFb1 (Pierce
et al., 1989; Salomon et al., 1990; Beck et al., 1991, 1993).
Based on the above studies, it is not surprising that TGFb1 has
long been considered as a promising potential therapeutic
agent for impaired wound healing. Despite that early studies
showing that injection of TGFb1 to wounds accelerate
healing in experimental animals (Mustoe et al., 1987; Sporn
and Roberts, 1993), clinical trials that exogenously adminis-
tered TGFb1 to human chronic ulcers have achieved very
limited efficacy (Bennett et al., 2003; Mulder, 2004).
Accumulating reports from recent studies begin to
challenge whether TGFb1 can be used as a therapeutic agent
for impaired wound healing. The first surprise was from
wound healing using Smad3 knockout mice, in which TGFb
signaling is partially abolished. Instead of a predicted delay in
healing, Smad3 null mice exhibited accelerated wound
healing, featured by increased keratinocyte proliferation
and migration, and reduced monocyte infiltration (Ashcroft
et al., 1999). Consistently, deletion of the secretory leukocyte
protease inhibitor, a molecule that is required for normal
wound healing, results in delayed wound healing that is
characterized with increased TGFb1 activation and can be
attenuated by TGFb1 antibody (Ashcroft et al., 2000). More
direct evidence comes from recent studies, in which
transgenic mice expressing the TGFb1 transgene in keratino-
cytes exhibited delayed healing after burn injury (Yang et al.,
2001; Tredget et al., 2005). Conversely, TGFb1 knockout
mice showed accelerated re-epithelialization during inci-
sional wound repair, in comparison with wild-type mice
(O’Kane and Ferguson, 1997; Koch et al., 2000). Thus,
ideally, a better wound-healing outcome may be achieved by
selectively blocking the negative effects of TGFb1. In
supporting this notion, transgenic mice overexpressing a
dominant-negative TGFb receptor exhibit accelerated re-
epithelialization in skin wounds. This is associated with an
increased proliferation and reduced apoptosis in keratino-
cytes at the wound edge owing to the resistance of
keratinocytes to TGFb-mediated growth arrest and apoptosis
(Amendt et al., 2002). Similarly, administration of exogenous
Smad7, the antagonist of TGFb signaling, to mouse eyes
accelerates corneal wound healing via promoting epithelial
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cell migration and inhibiting monocyte/macrophage invasion
to the wounds (Saika, 2004; Saika et al., 2005). Taken
together, selective suppression of TGFb signaling in certain
cell types in cutaneous wounds may benefit wound healing
despite the dogma that TGFb plays a key role in wound
healing.
CONSTITUTIVE OVEREXPRESSION OF TGFb1 IN
KERATINOCYTES DELAYED CUTANEOUS WOUND
HEALING OWING TO AT LEAST, IN PART, ELICITING
SKIN INFLAMMATION
Previously reported studies have prompted us to speculate
that endogenous TGFb1 may have a negative impact on
wound healing at least partially owing to its role in the
induction of inflammation. TGFb1 has long been known for
its dual effects on inflammatory response and immune
modulation. The pro-inflammatory effect of TGFb1 has been
overlooked ever since studies have shown that TGFb1
knockout mice exhibit inflammation in multiple organs and
autoimmune conditions, which highlight an anti-inflamma-
tory role of TGFb1 (Shull et al., 1992; Kulkarni et al., 1993).
However, the in vivo role of TGFb1 in regulating inflamma-
tory/immune response may vary in different organs. For
instance, TGFb1 knockout mice do not develop any
inflammatory phenotypes in the skin (Shull et al., 1992;
Kulkarni et al., 1993) and are devoid of Langerhans cells in
the epidermis (Borkowski et al., 1996, 1997). Considering
that TGFb1 is a potent chemotactic cytokine for virtually all
leukocytes as well as endothelial cells and fibroblasts (Wahl
et al., 1987, 1993; Wahl, 1992, 1994), all of which are
involved in the development of inflammation, the pro-
inflammatory effect of TGFb1 is likely to predominate in
the skin. In supporting this notion, overexpression of TGFb1
in basal keratinocytes and hair follicles initiates chronic skin
inflammation, marked by epidermal hyperplasia, leukocyte
infiltration, and angiogenesis (Liu et al., 2001; Li et al., 2004).
In addition, we observed that during cutaneous wound
healing, endogenous TGFb1 increased rapidly upon injury
and reached a peak level 3 days post a 6-mm full-thickness
wounding (Figure 1), which coincide with the peak of the
inflammation phase during early stages of wound healing.
We further assessed the wound-healing process in
K5.TGFb1wt transgenic mice, which spontaneously develop
an inflammatory skin disorder (Li et al., 2004). Notably,
almost all K5.TGFb1wt mice developed spontaneous skin
ulcers in the friction-prone areas by 4–5 months of age
(Figure 2). Histology on skin ulcers revealed an absence of
epidermis, massive inflammatory cells in the dermis, and
prominent angiogenesis, resembling granulation tissues dur-
ing wound healing (Figure 2). We then performed wound-
healing studies using 6-mm punch biopsies on the dorsal skin
of 8-week-old transgenic mice and non-transgenic litter-
mates. At this age, the hair follicles are synchronized at the
telogen (resting) phase (Muller-Rover et al., 2001), and the
inflammation and epidermal hyperplasia are not yet severe in
transgenic skin. Five mice in each group were evaluated at
each post-wounding time point. Both male and female mice
were used in the study, and there was no noticeable
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Figure 1. Expression levels of endogenous TGFb1 determined by ELISA on
wound biopsies. Total protein was extracted from individual wound biopsies
from normal ICR mice at different time points. The value at each time point
represents the average level of TGFb1 detected in samples from three mice.
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Figure 2. K5.TGFb1wt mice developed spontaneous skin ulcers and showed
delayed re-epithelialization upon wounding. (a) A K5.TGFb1wt mouse
displayed spontaneous skin ulcers. (b) Histological analysis of non-ulcerated
transgenic skin showed epidermal hyperplasia, hyperkeratosis, acanthosis,
and a diminished basement membrane. Numerous neutrophils were observed
in both the epidermis (white arrow) and dermis (black arrows in the inset).
(c) Histological analysis of ulcerated skin of a transgenic mouse revealed
epidermal necrosis (open arrow), numerous inflammatory cells, and increased
angiogenesis (asterisks indicate clustered red blood cells). The bar in panel (b)
represents 40 mm for both (b) and (c). To further study the effects of TGFb1
overexpression on cutaneous wound healing, both non-transgenic (N) and
K5.TGFb1wt (T) mice were subjected to 6-mm full-thickness wounding and
monitored for wound closure daily. (d) Macroscopic changes in skin wounds
in a non-transgenic littermate and a K5.TGFb1wt mouse. (e) Changes in
wound area (mm2) at each time point. The data of each time point represents
the average from five mice. (f) Proliferating cell nuclear antigen staining of
day 3 wounds revealed a decreased number of positive nuclei (brown cells,
arrows point out examples) of the wound edge in transgenic epidermis as
compared to that of non-transgenic epidermis. The dotted line delineates the
boundary between the epidermis and the dermis. Proliferating cell nuclear
antigen staining at other time points provided similar results (data not shown).
The bar represents 25 mm for both immunohistochemical sections.
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difference in the wound healing kinetics between the sexes.
Wound closure in non-transgenic mice occurred visibly
during the first week, whereas the wound areas were barely
changed in K5.TGFb1wt mice (Figure 2). The scabs on non-
transgenic wounds detached at about day 10 post-wounding,
but the scabs remained on transgenic wounds, even at day 21
post-wounding. Consistent with delayed wound closure,
immunohistochemistry with an antiproliferating cell nuclear
antigen–antibody revealed an approximately 3-fold decrease
in keratinocyte proliferation in the migrating tongue of
K5.TGFb1wt wounds compared to that in non-transgenic
wounds (Figure 2). This observation is in contrary to that
observed in unwounded skin, in which TGFb1wt induces
expression of growth factors from fibroblasts and leukocytes,
resulting in epidermal hyperplasia (Li et al., 2004). Therefore,
it appears that these growth factors are not sufficient to
overcome TGFb1-induced growth inhibition at the wound
edge where keratinocytes demand a higher proliferation rate
(Figure 2). Microscopically, K5.TGFb1wt wounds displayed
delayed re-epithelialization and prolonged granulation tissue
accompanied by a persistent inflammatory cell infiltration
throughout in comparison with non-transgenic wounds
(Figure 3).
Our data suggest that the delayed cutaneous wound
healing in K5.TGFb1wt mice can be partially attributed to
excessive inflammation throughout all stages of wound
healing (Figure 3). For instance, inflammatory cells, espe-
cially macrophages at sites of injury, produce a large amount
of MMPs, which may overdigest the basement membrane
between the newly formed epidermis and the underlying
granulation tissue, thereby suppressing re-epithelialization to
cover the wound. This is consistent with an upregulation of
genes encoding MMP2, MMP3, and MMP9, and a rapid
degradation of the basement membrane in K5.TGFb1wt
transgenic skin (Li et al., 2004). Specifically, MMP9 knockout
mice showed an accelerated epithelial cell migration in
corneal wounds in association with reduced Smad2-
mediated signaling, suggesting a suppressive role of MMP9
in re-epithelialization during wound healing (Mohan et al.,
2002). More importantly, elevated levels of MMPs, including
MMP2 and MMP9, have been reported in wounds of human
chronic ulcers, and MMP inhibitors have been considered for
a new therapy (Mandal et al., 2003). In addition, excessive
TGFb1 and other inflammatory cytokines expressed by
inflammatory cells may directly inhibit expression of genes
that promote keratinocyte migration.
FUTURE PERSPECTIVES
The controversial data on the effects of TGFb1 on cutaneous
wound healing may reflect the complex nature of biological
functions of TGFb1, which may be cell type and context
specific. As keratinocytes are one of the major sources of
TGFb1 after cutaneous injury (O’Kane and Ferguson, 1997),
transgenic mouse models that overexpress TGFb1 in kerati-
nocytes will provide experimental tools to explore the
molecular mechanisms of the effects of TGFb signaling on
wound healing. In previous studies, TGFb1 expression levels
were not temporally controlled, which makes it difficult to
determine the direct effect of TGFb1 at each specific stage.
For instance, constitutive overexpression of TGFb1 may result
in excessive inflammation, which will over-ride other
positive effects of TGFb1 on wound healing. Furthermore,
expression levels of TGFb1 may also affect its functions. To
study the role of TGFb1 in wound healing in a stage-specific
manner in the future, we developed a ‘‘gene-switch’’
transgenic system, which allows inducible expression of a
transgene in keratinocytes temporally and for transgene
expression levels to be controlled (Wang et al., 1999; Lu
et al., 2004). Through inducing transgene expression at
different levels and at different time points after skin punches
on gene-switch transgenic mice, we will be able to analyze
the effects of TGFb1 on different wound-healing stages,
including inflammation, tissue formation, and tissue remo-
deling. These studies will provide unique insights into a better
understanding of stage- and dose-specific effects of TGFb1 on
skin wound healing, which will facilitate the development of
new therapies for impaired wound healing through modulat-
ing TGFb-elicited signaling.
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